Non-myeloablative hematopoietic stem cell transplantation is of limited value in advanced or refractory acute myeloblastic leukemia. The Mexican experience

References

• Harousseau JL, Cahn JY, Pignon B, et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucemies Aigues Myelo-blastiques (GOELAM). Blood 1997;90:2978–2986.
   Google Scholar
• Ravindranath Y, Yeager AM, Chang MN, Steuber P, Krischer J, Graham-Pole J, et al. For The Pediatric Oncology Group. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. N Engl J Med 1996;334:1428–1434.
   Google Scholar
• Cassileth PA, Harrington DP, Appelbaum FR, Lazarus HM, Rowe JM, Paietta E, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998;339:1649–1656.
   PubMed Web of Science ®Google Scholar
• Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R, Kashyap A, Flowers MED, Lilleby K, Chauncey TR, Storb R, Applebaum FR Transplantation of bone marrow as compared with peripheral blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001;344:175–181.
   PubMed Web of Science ®Google Scholar
• Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD, et al. Antileukemic effect of graft-versus-host-disease in human recipients of allogeneic marrow grafts. N Eng J Med 1979;300:1068–1073.
   PubMed Web of Science ®Google Scholar
• Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, et al. Graft-versus leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European group for blood and marrow transplantation working party chronic leukemia. Blood 1995;86:2041–2050.
   Google Scholar
• Long G, Blume K. Allogeneic bone marrow transplantation for acute myeloid leukemia. In: Forman S, Blume K, Thomas E, editors. Bone marrow transplantation. Boston, MA: Blacwell Scientific; 1994. p 607.
   Google Scholar
• Giralt SA, Champlin RE. Leukemia relapse after allogeneic bone marrow transplantation: A review. Blood 1994;84:3603–3612.
   PubMed Web of Science ®Google Scholar
• Miller KB, Daust PH. Clinical manifestations of acute leukemia Hematology: Basic principles and practice. 4th ed. Amsterdam, The Netherlands: Elsevier; 2005. p 1090.
   Google Scholar
• Shulman HM, Sullivan KM, Weiden PL. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980;69: 204–217.
   PubMed Web of Science ®Google Scholar
• Cutler C, Antin JH. Peripheral blood stem cells for allogeneic transplantation: A review. Stem Cells 2001;19:108–117.
   PubMed Web of Science ®Google Scholar
• Gluncksberg H, Storb R, Fefer A. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974;18: 295–304.
   Google Scholar
• Ruiz-Arguelles GJ, Gómez-Almaguer D, Ruiz Arguelles A. Results of an outpatient based stem cell allotransplant program using non-myeloablative conditioning regimens. Am J Hema-tol 2001;66:241–244.
   PubMed Web of Science ®Google Scholar
• Ruiz-Argiielles GJ, GOmez-Almaguer D, Lopez-Martinez B. Results of an allogeneic non-myeloablative stem cell trans-plantation program in patients with chronic myelogenous leukemia. Haematologica 2002;87:894–896.
   Google Scholar
• Ruiz-Argiielles GJ. Allogeneic stem cell transplantation using non-myeloablative conditioning regimens: Results of the Mexican approach. Int J Hematol 2002;76\(suppl 1): 376–379.
   Google Scholar
• GOmez-Almaguer D, Ruiz-Argiielles GJ, Tarin-Arzaga LC. Reduced-intensity stem cell transplantation in children and adolescents: The Mexican experience. Biol Blood Marrow Transplant 2003;9:157–161.
   PubMed Web of Science ®Google Scholar
• Giralt S, Estey E, Albitar M. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997;89:4531–4536.
   Google Scholar
• Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrowtransplantation with lethal cytorreduction for the treatment of malignant and nonmalignant hematological diseases. Blood 1998;91:756–763.
   PubMed Web of Science ®Google Scholar
• Kessinger A, Armitage JO, Landmark JD, et al. Autologus peripheral hematopoietic stem cell transplantation restores hemopoietic function following marrow ablative therapy. Blood 1998;71:723–727.
   Google Scholar
• Ordemman R, Hölig K, Wagner K. Acceptance and feasibility of peripheral stem cell mobilization compared to bone marrow collection from healty unrelated donors. Bone Marrow Transplant 1998;21:S25—S28.
   PubMed Web of Science ®Google Scholar
• Auquier P, Macquart-Moulin G, Moatti JP, et al. Comparision of anxiety, pain and discomfort in two procedures of hematopoietic stem cell collection: Leukacytapheresis and bone marrow harvest. Bone Marrow Transplant 1995;16:541–547.
   PubMed Web of Science ®Google Scholar
• Giralt SA, LeMaistre CF, Vriesendorp HM, Andersson BS, Dimopoulos M, Gajewski J, et al. Etoposide, ciclopho-sphamide, total-body irradiation, and allogeneic bone marrow transplantation for hematologic malignancies. J Clin Oncol 1994;12:1923–1930.
   PubMed Web of Science ®Google Scholar
• Yau JC, LeMaistre CF, Andersson BS. Allogeneic bone marrow transplantation for hematological malignancies fol-lowing etoposide, ciclophosphamide and fractionated total body irradiation. Am J Hematol 1992;41:40–44.
   Google Scholar
• Solano C, Martinez C, Brunet S, Tomis JF, Urbano-Izpizua A, Zuazu J, et al. For The Spanish Group of Allo-PBT. Chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell or bone marrow transplantation from matched related donors. A case control study. Bone Marrow Transplant 199822:1129–1135.
   PubMed Web of Science ®Google Scholar
• Brown RA, Adkins D, Khoury H, Vij R, Goodnough LT, Shenoy S, et al. Long-term follow-up of high-risk allogeneic peripheral-blood stem-cell transplant recipients: Graft-versus-host disease and transplant-related mortality. J Clin Oncol 1999;17:806–812.
   PubMed Web of Science ®Google Scholar
• Champlin RE, Schmitz N, Horowitz M, Chapuis B, Chopra R, cornelissen JJ, et al. For the IBMTR histocompatibility and stem cell sources working committee and European group for blood and marrow transplantation (the EBMT). Blood stem cell compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. Blood 2000;95:3702–3709.
   Google Scholar
• Majolino I, Saglio G, Scime R. High incidence of chronic GVHD after primary allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies. Bone Marrow Transplant 1996;17:555–560.
   Google Scholar
• Chao N, Forman S. Allogeneic bone marrow transplantation for acute lymphoblastic leukemia. In: Forman S, Blume K, Thomas E, editors. Bone marrow transplant. Boston, MA: Blackwell Scientific; 1994. p 618.
   Google Scholar
• Ruiz Argilelles G, Gómez Almaguer D, Gómez Range! J. Allogeneic hematopoietic stem cell transplantation with non-myeloablative conditioning in patients with acute myelogenous leukemia eligible for conventional allo-grafting: A prospective study. Leuk Lymphoma 2004; 45:1191–1195.
   PubMed Web of Science ®Google Scholar